Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2023 Earnings Call Transcript February 26, 2024 8:30 AM ET

Company Participants

Meg Dodge - Head of IR & Corporate Communications

Krish Krishnan - Chairman and CEO

Suma Krishnan - President of R&D

Kate Romano - Chief Accounting Officer

Conference Call Participants

Alec Stranahan - Bank of America

Dae Gon Ha - Stifel

Joe Pantginis - HC Wainwright

Andrea Tan - Goldman Sachs

Tim Lugo - William Blair

Gavin Clark-Gartner - Evercore ISI

Josh Schimmer - Cantor

Operator

Thank you for standing by and welcome to the Krystal Biotech Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all participants are on a lesson-only mode. After the speakers' presentations, there will be a question-and-answer session. As a reminder, today's conference is being recorded.

I would now like to hand the conference over to your host, Meg Dodge, Head of Investor Relations and Corporate Communications. Please begin.

Meg Dodge

Good morning, and thank you all for joining today's call. Earlier today, we released our financial results for the fourth quarter and full year of 2023. The press release is available on our website at www.krystalbio.com. Our earnings 8-K was filed earlier today, and additionally we filed a 10-K with the SEC.

Joining me will be Krish Krishnan, Chairman and Chief Executive Officer; Suma Krishnan, President of Research and Development; and Kate Romano, Chief Accounting Officer.

I'd like to note, during this webcast we will be making a number of forward-looking statements about our future business plans, strategies, financial performances and projections, product candidate development plans, including statements about VYJUVEK. These forward-looking statements involve risks and uncertainties, any of which are beyond Krystal's control. Actual results could materially differ from these forward-looking statements, as any -- and such risk can material and adversely affect the business, results of operations, and trading price of Krystal's common stock. For a detailed description of applicable risks and uncertainties, we encourage you to review our SEC filings. The company does not undertake any obligation to publicly update its forward-looking statements, including any financial projections provided today based on subsequent events or circumstances.

With that, let me now turn the call over to Krish.

Krish Krishnan

Meg, thank you. Good morning and thanks for joining the Krystal’s earnings call. 2023 was a spectacular year for Krystal and an inflection point for our company. With the approval and launch of VYJUVEK for the treatment of dystrophic epidermolysis bullosa, or DEB, we've now brought to market the first and only treatment that addresses the genetic cause of this debilitating disease. It has been immensely rewarding to hear from patients, families, and the entire DEB community on the positive impact VYJUVEK has had on their lives.